ArriVent BioPharma has entered a partnership with Alphamab Oncology subsidiary Jiangsu Alphamab Biopharmaceuticals for the discovery, development and marketing of new antibody-drug conjugates (ADCs) to treat cancer.

The partnership will utilise the linker-payload platform and glycan-conjugation technology of Alphamab to detect promising ADC candidates for oncology indications.

ArriVent will obtain sole worldwide rights for developing and commercialising the ADCs developed through the partnership.

Mainland China, Hong Kong, Macau and Taiwan are excluded and remain under Alphamab’s jurisdiction for the development and commercialisation of the ADCs.

ArriVent chairman and CEO Bing Yao stated: “This exciting collaboration strengthens and complements our pipeline with the potential to add multiple innovative new ADC programmes, and exemplifies our strategic model of identifying and developing potential first and best-in-class product candidates from across the globe.

“We look forward to complementing the research and discovery capabilities of Alphamab with our global drug development and commercialisation expertise to address the unmet needs of cancer patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The financial structure of the deal includes up to $615.5m in combined upfront and potential milestone payments to Alphamab.

The payments are contingent upon reaching specific regulatory, development and sales-based targets across the potential programmes.

Alphamab is entitled to receive tiered royalty payments based on product sales from ArriVent for each ADC product commercialised under the collaboration.

Alphamab Oncology founder, chairman and CEO Ting Xu stated: “ArriVent shares our passion for developing differentiated, clinically valuable and globally competitive new drugs.

“This collaboration, based on Alphamab’s proprietary and clinically validated glycan-conjugation platform, combined with ArriVent’s deep knowledge in oncology and extensive development experience, provides us with the opportunity to work together to deliver important new oncology therapeutics to patients.”